Status:

COMPLETED

Neuromuscular Fatigue in Chronic Obstructive Pulonary Disease

Lead Sponsor:

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Collaborating Sponsors:

Université de Toulon

Conditions:

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility:

All Genders

40+ years

Phase:

NA

Brief Summary

Fatigue is a prevalent symptom in Chronic Obstructive Pulmonary Disease (COPD) that limits patients in their daily living activities. It is now well established that COPD patients may have altered neu...

Detailed Description

This study will include three experimental sessions for both COPD patients and healthy participants. These experimental sessions will be performed on three separate days. Each session will last betwee...

Eligibility Criteria

Inclusion

  • COPD patients :
  • GOLD II - III or IV
  • FEV1 \<80% of predicted values
  • Men and women aged 40 years and over
  • French-speaking participant
  • BMI \<30 kg / m²
  • Stable condition (i.e. without exacerbation) for more than 15 days
  • Able to express their consent in writing prior to any participation in the study
  • Affiliates or beneficiaries of a social security
  • Minimum score of 26 on the MMSE questionnaire of 3 months or less
  • Healthy volunteers :
  • Men and women aged 40 years and over
  • French-speaking participant
  • BMI \<30 kg / m²
  • No known chronic respiratory, cardiovascular, metabolic, renal or neuromuscular pathologies
  • Able to express their consent in writing prior to any participation in the study
  • Affiliates or beneficiaries of a social security
  • Minimum score of 26 on the MMSE questionnaire of 3 months or less

Exclusion

  • COPD patients :
  • Alcoholism, i.e. \> 21 glasses a week for men and \>14 glasses a week for women
  • Psychiatric pathologies or antecedent of behavioral disorders
  • Patients treated with oral or systemic corticosteroids (\> 0.5 mg / kg / day for \> 7 days)
  • Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries)
  • Severe vision or hearing problems not corrected
  • Patient oxygen dependent
  • Patients in exclusion period from another research protocol
  • Pregnant women (known pregnancy) or lactating women
  • Patient deprived of liberty by a judicial or administrative decision
  • Patient subject to a legal protection measure or unable to express their consent
  • Patient who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study
  • Patient unable to follow study procedures and to respect visits throughout the study period
  • Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study
  • Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study
  • Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study
  • Healthy volunteers:
  • Alcoholism, i.e. \> 21 glasses a week for men and \>14 glasses a week for women
  • Psychiatric pathologies or antecedent of behavioral disorders
  • Patients treated with oral or systemic corticosteroids (\> 0.5 mg / kg / day for \> 7 days)
  • Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries)
  • Severe vision or hearing problems not corrected
  • Subjects in exclusion period from another research protocol
  • Pregnant women (known pregnancy) or lactating women
  • Regular physical activity with a frequency greater than 3 sessions per week
  • Participant deprived of liberty by a judicial or administrative decision
  • Participant subject to a legal protection measure or unable to express their consent
  • Participant who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study
  • Participant unable to follow study procedures and to respect visits throughout the study period
  • Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study
  • Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study
  • Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study

Key Trial Info

Start Date :

September 16 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 17 2023

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04028973

Start Date

September 16 2020

End Date

February 17 2023

Last Update

January 28 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Université de Toulon, laboratoires LAMHESS et IAPS

La Garde, Var, France, 83130

2

Hôpital d'Instruction des Armées Sainte-Anne

Toulon, Var, France, 83000